Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 87

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 87
---
The shares of Common Stock being offered hereby are those issuable to the Selling Stockholders upon exercise of the Common Warrants. For additional information regarding the issuances of the Common Warrants, see “The March 2024 Offerings,” “The August 2024 Offerings” and “The October 2024 Offerings” above. We are registering the shares of Common Stock in order to permit the Selling Stockholders to offer the shares of Common Stock for resale from time to time.

Except for the ownership of the Common Warrants, shares of Common Stock and warrants purchased in our initial public offering, and the shares of Common Stock and/or warrants issued in registered direct offerings and/or private placement offerings subsequent to our initial public offering, including the March 2024 Offerings, the August 2024 Offerings and the October 2024 Offerings, the Investors have not had any material relationship with us within the past three years.

Except as described below, WallachBeth and its designees have not had any material relationship with us within the past three years.WallachBeth served as: (i) the placement agent in connection with our sale of convertible bridge notes in 2021 and 2022, (ii) the underwriter for our initial public offering that closed on September 6, 2022; (iii) the placement agent for our March 2024 Offerings; (iv) financial advisor and placement agent for our August 2024 Offerings, (v) as placement agent for the October 2024 Offerings, and (vi) as placement agent for the transactions contemplated by the February Inducement Agreement, pursuant to which WallachBeth received cash compensation and warrants. See the sections entitled “The March 2024 Offerings,” “The August 2024 Offerings” and “The October 2024 Offerings” above for more information about the compensation received in connection with such offerings.

The following table sets forth, to our knowledge, information concerning the beneficial ownership of shares of our Common Stock by the Selling Stockholders as of June 27, 2025. The information in the table below with respect to the Selling Stockholders has been obtained from the Selling Stockholders and we have prepared the following table based on the information supplied to us by the Selling Stockholders on or prior to June 27, 2025. When we refer to the “Selling Stockholders” in this prospectus, or, if required, a post-effective amendment to the registration statement of which this prospect